

tive MRSA isolates and that genotypes for some CA-MRSA strains are shared by a few of the MSSA strains (1).

The experimental work was conducted in the Department of Microbiology, University of Hong Kong, and supported by grants from the University Development Fund Project—Research Centre of Emerging Infectious Diseases of the University of Hong Kong.

**Li-Zhong Han, Pak-Leung Ho,  
Yu-Xing Ni, Hong Zhang,  
Yan-Qun Jiang, Hai-Qing Chu,  
Yang Sun, and Yi-Bo Zhang**

Author affiliations: Ruijin Hospital, Shanghai, People's Republic of China (L.-Z. Han, Y.-X. Ni, Y.-B. Zhang); University of Hong Kong, Hong Kong Special Administrative Region, PRC (P.-L. Ho); Shanghai Children's Hospital, Shanghai (H. Zhang); Sixth People's Hospital of Shanghai, Shanghai (Y.-Q. Jiang); Shanghai Pulmonary Hospital, Shanghai (H.-Q. Chu); and Minhang Central Hospital, Shanghai (Y. Sun)

DOI: 10.3201/eid1604.081324

#### References

1. Ho PL, Chuang SK, Choi YF, Lee RA, Lit AC, Ng TK, et al. Community-associated methicillin-resistant and methicillin-sensitive *Staphylococcus aureus*: skin and soft tissue infections in Hong Kong. *Diagn Microbiol Infect Dis*. 2008;61:245–50. DOI: 10.1016/j.diagmicrobio.2007.12.015
2. Tristan A, Bes M, Meugnier H, Lina G, Bozdogan B, Courvalin P, et al. Global distribution of Pantone-Valentine leukocidin-positive methicillin-resistant *Staphylococcus aureus*, 2006. *Emerg Infect Dis*. 2007;13:594–600. DOI: 10.3201/eid1304.061316
3. Ho PL, Lai EL, Chow KH, Chow LS, Yuen KY, Yung RW. Molecular epidemiology of methicillin-resistant *Staphylococcus aureus* in residential care homes for the elderly in Hong Kong. *Diagn Microbiol Infect Dis*. 2008;61:135–42. DOI: 10.1016/j.diagmicrobio.2007.12.017
4. Ho PL, Wang TK, Ching P, Mak GC, Lai E, Yam WC, et al. Epidemiology and genetic diversity of methicillin-resistant *Staphylococcus aureus* strains in residential care homes for elderly persons in Hong Kong. *Infect Control Hosp Epidemiol*. 2007;28:671–8. DOI: 10.1086/517951

5. Finlay JE, Miller LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. *Antimicrob Agents Chemother*. 1997;41:1137–9.
6. Perez-Roth E, Claverie-Martin F, Villar J, Mendez-Alvarez S. Multiplex PCR for simultaneous identification of *Staphylococcus aureus* and detection of methicillin and mupirocin resistance. *J Clin Microbiol*. 2001;39:4037–41. DOI: 10.1128/JCM.39.11.4037-4041.2001
7. Denis O, Deplano A, De Beenhouwer H, Hallin M, Huysmans G, Garrino MG, et al. Polyclonal emergence and importation of community-acquired methicillin-resistant *Staphylococcus aureus* strains harbouring Pantone-Valentine leukocidin genes in Belgium. *J Antimicrob Chemother*. 2005;56:1103–6. DOI: 10.1093/jac/dki379
8. Yu F, Chen Z, Liu C, Zhang X, Lin X, Chi S, et al. Prevalence of *Staphylococcus aureus* carrying Pantone-Valentine leukocidin genes among isolates from hospitalised patients in China. *Clin Microbiol Infect*. 2008;14:381–4. DOI: 10.1111/j.1469-0691.2007.01927.x
9. Zaoutis TE, Toltzis P, Chu J, Abrams T, Dul M, Kim J, et al. Clinical and molecular epidemiology of community-acquired methicillin-resistant *Staphylococcus aureus* infections among children with risk factors for health care-associated infection: 2001–2003. *Pediatr Infect Dis J*. 2006;25:343–8. DOI: 10.1097/01.inf.0000207403.67197.cc
10. Ghebremedhin B, Olugbosi MO, Raji AM, Layer F, Bakare RA, König B, et al. Emergence of a community-associated methicillin-resistant *Staphylococcus aureus* strain with a unique resistance profile in Southwest Nigeria. *J Clin Microbiol*. 2009;47:2975–80. DOI: 10.1128/JCM.00648-09

Address for correspondence: Pak-Leung Ho, Division of Infectious Diseases, Department of Microbiology, Queen Mary Hospital, The University of Hong Kong, Pokfulam Rd, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China; email: plho@hkucc.hku.hk



## *Clostridium difficile* in Ground Meat, France

**To the Editor:** *Clostridium difficile* is a toxigenic enteropathogen responsible for 15%–20% of antimicrobial drug-associated diarrhea and for almost all cases of pseudomembranous colitis. Two protein toxins (TcdA and TcdB) play a major role in the pathogenesis of infections. *C. difficile* is also recognized as a cause of disease in several animal species, which could be potential reservoirs (1). In the past few years, the presence of *C. difficile* in raw diets for dogs and cats and in retail meat sold for human consumption has been reported in the United States and Canada at rates from 6% to 42% (2–5). To determine *C. difficile* contamination of meat in France, we evaluated 105 packages of ground beef (vacuum packed or not), 59 pork sausages, and 12 packages of feline raw diet meat purchased from 20 urban and suburban Paris retail stores and supermarkets during September 2007–July 2008.

*C. difficile* spores or vegetative forms in samples were found as described by Rodriguez-Palacios et al. (4). Briefly, 5 g of each sample was cultured in 100 mL of prereduced brain–heart infusion (BHI) broth supplemented with cefoxitin (10 µg/mL), cycloserine (250 µg/mL), and taurocholate (0.1%). After the samples were incubated under anaerobic conditions at 37°C for 72 h, subculturing with and without alcohol shock for spore selection was performed. The BHI broth culture was treated with 2 mL of absolute ethanol (1:1 vol/vol) for 30 min and centrifuged at 3,800 × g for 10 min, and the pellet was resuspended in 200 µL of prereduced BHI broth. Serial dilutions of the BHI broth and the pellet were injected onto Columbia cysteine agar supplemented with cefoxitin-cycloserine, taurocholate, and 5% horse blood and incubated anaerobically for 48 h at 37°C.

*C. difficile* colonies were identified classically, and susceptibilities to moxifloxacin, teicoplanin, vancomycin, metronidazole, linezolid, levofloxacin, telithromycin, erythromycin, and lincomycin were determined by the agar disk-diffusion methods described by the French Society for Microbiology ([www.sfm.asso.fr](http://www.sfm.asso.fr)). PCR amplifications of a species-specific internal fragment of the triose phosphate isomerase (*tpi*) gene, an internal fragment of the toxin B (*tcdB*) gene, and the 3' region of the toxin A (*tcdA*) gene were performed as described by Lemeé et al. (6). Strains were characterized by toxinotyping according to Rupnik et al. (7) and PCR-ribotyping as described by Bidet et al. (8).

The detection threshold of the enrichment method was established by spiking known uninfected samples (ground beef, pork sausage, and feline raw diets) with vegetative cells and spores of *C. difficile* (VPI 10463 strain). For ground beef samples, the detection thresholds for vegetative forms and spores were 2 CFU/5 g and 4.5 CFU/5 g of meat, respectively. For pork sausages, the detection thresholds were 14 CFU/5 g and 38 CFU/5 g of sample after 72 h, for vegetative forms and spores, respectively. For feline raw diets, the detection threshold of spores was 2 CFU/5 g of sample. In addition, toxin B was detected in the culture supernatants by the cytotoxicity assay onto MRC-5 cells. Toxin detection showed 100% agreement with the culture method.

*C. difficile* was not detected in pork sausages or in commercial feline raw diets. *C. difficile* was isolated from 2 (1.9%) of 105 ground beef, but only from those packages that were vacuum packed. The anaerobic atmosphere of vacuum packaging could facilitate the survival of *C. difficile* and the germination of spores. These 2 isolates were fully susceptible to moxifloxacin, teicoplanin, vancomycin, metronidazole, and linezolid but resistant to levofloxacin, telithromycin, erythromycin,

and lincomycin. They harbored genes encoding for Tpi protein and for TcdA and TcdB. The 2 strains belonged to the toxinotype 0 and PCR-ribotype 012. Toxinotype 0 was already identified in meat samples in Canada (4). PCR-ribotype 012 belongs to the 10 ribotypes most frequently isolated from humans (9).

The prevalence of *C. difficile* in ground meat in France is low compared with the prevalence reported by other countries. In Canada, Rodriguez-Palacios et al. (4) studied 60 beef samples and found the prevalence of *C. difficile* to be 20%. These same authors, by using a broader sampling scheme (214 meat samples), isolated *C. difficile* from 6% of the samples (5). Also in Canada, Weese et al. (10) reported that 12% of ground beef and ground pork samples were contaminated. In the United States, *C. difficile* was isolated from 42% of meat samples (beef, pork, and turkey products) (3).

For a better understanding of the sources of *C. difficile* in France, it would be interesting to determine its prevalence in different animal fecal samples and the toxinotypes associated with animals. The low prevalence in retail meat in France could result from hazard analysis critical control point principles and microbiologic quality controls implemented throughout the food production chain, which help reduce the spread of *C. difficile* and minimize the risk for infection for the consumer.

**Sylvie Bouttier,  
Marie-Claude Barc,  
Benjamin Felix, Sylvie Lambert,  
Anne Collignon,  
and Frédéric Barbut**

Author affiliations: Université Paris-Sud 11, Châtenay-Malabry, France (S. Bouttier, M.-C. Barc, S. Lambert, A. Collignon); and Hôpital Saint-Antoine, Paris, France (B. Félix, F. Barbut)

DOI: 10.3201/eid1604.091138

## References

1. Jhung MA, Thompson AD, Killgore GE, Zubowski WE, Songer G, Warny M, et al. Toxinotype V *Clostridium difficile* in humans and food animals. *Emerg Infect Dis.* 2008;14:1039–45. DOI: 10.3201/eid1407.071641
2. Weese JS, Rousseau J, Arroyo L. Bacteriological evaluation of commercial canine and feline raw diets. *Can Vet J.* 2005;46:513–6.
3. Songer JG, Trinh HT, Killgore GE, Thompson AD, McDonald C, Limbago BM. *Clostridium difficile* in retail meat products, USA, 2007. *Emerg Infect Dis.* 2009;15:819–21. DOI: 10.3201/eid1505.081071
4. Rodriguez-Palacios A, Staempfli HR, Duffield T, Weese JS. *Clostridium difficile* in retail ground meat, Canada. *Emerg Infect Dis.* 2007;13:485–7. DOI: 10.3201/eid1303.060988
5. Rodriguez-Palacios A, Reid-Smith RJ, Staempfli HR, Martin H, Daignault D, Janecko N, et al. Possible seasonality of *Clostridium difficile* in retail meat, Canada. *Emerg Infect Dis.* 2009;15:802–5. DOI: 10.3201/eid1505.081084
6. Lemeé L, Dhalluin A, Testelin S, Matrat MA, Maillard K, Lemeland JF, et al. Multiplex PCR targeting *tpi* (triose phosphate isomerase), *tcdA* (toxin A), and *tcdB* (toxinB) genes for toxigenic culture of *Clostridium difficile*. *J Clin Microbiol.* 2004;42:5710–4. DOI: 10.1128/JCM.42.12.5710-5714.2004
7. Rupnik M, Avesani V, Janc M, von Eichel-Streiber C, Delmée M. A novel toxinotyping scheme and correlation of toxinotypes with serogroups of *Clostridium difficile* isolates. *J Clin Microbiol.* 1998;36:2240–7.
8. Bidet P, Lalande V, Salauze B, Burghoffer B, Avesani V, Delmée M, et al. Comparison of PCR-ribotyping, arbitrarily primed PCR and pulsed-field gel electrophoresis for typing *Clostridium difficile*. *J Clin Microbiol.* 2000;38:2484–7.
9. Barbut F, Mastrantonio P, Delmée M, Brazier J, Kuijper E, Poxton I. European Study Group on *Clostridium difficile* (ESGCD). Prospective study of *Clostridium difficile* infections in Europe with phenotypic and genotypic characterisation of the isolates. *Clin Microbiol Infect.* 2007;13:1048–57. DOI: 10.1111/j.1469-0691.2007.01824.x
10. Weese JS, Avery BP, Rousseau J, Reid-Smith RJ. Detection and enumeration of *Clostridium difficile* in retail beef and pork. *Appl Environ Microbiol.* 2009;75:5009–11. DOI: 10.1128/AEM.00480-09

Address for correspondence: Sylvie Bouttier, Faculté de Pharmacie, Université Paris-Sud 11, 5 rue Jean-Baptiste Clément, 92290 Châtenay-Malabry, France; email: sylvie.bouttier@u-psud.fr

## WUPyV in Children with Acute Respiratory Tract Infections, China

**To the Editor:** WU polyomavirus (WUPyV) is a human polyomavirus first detected in respiratory samples in 2007 (1). It has since been detected worldwide (2–7), including the People's Republic of China (8), but whether it is a causative respiratory pathogen remains speculative. To investigate the potential role of WUPyV in respiratory diseases and its prevalence in Tianjin, China, we examined samples obtained from children with upper respiratory tract infections (URTIs) and lower respiratory tract infections (LRTIs) by using PCR for the VP2 and LTA<sub>g</sub> genes, as described previously (1). As a control, we also tested samples from patients who did not have respiratory diseases.

Case-patients were 174 inpatients, hospitalized for LRTIs March–April 2008 and September 2008–February 2009, and 68 outpatients treated for URTIs November–December 2009 at Tianjin Children's Hospital. Controls were 43 outpatients with illnesses other than respiratory diseases treated at Tianjin Xianshuigu Hospital. Most patients with LRTIs had pneumonia or bronchitis. Case-patient age ranged from 3 hours to 12 years; for 1 patient, age was unknown (Table). Nasopharyngeal aspirate samples were collected from hospitalized children, and throat swabs were obtained from out-

patients with URTIs and from control children.

Of the 174 nasopharyngeal aspirate specimens tested, 28 (16%) had WUPyV VP2 gene-positive fragments; 24 had LTA<sub>g</sub> gene-positive fragments. Four VP2-positive but LTA<sub>g</sub>-negative fragments were sequenced; nucleotide sequences were identical to WUPyV strains in GenBank. Mean age of WUPyV-infected patients was 11.7 months (range 12 days–39 months); 10 patients (36%) were ≤6 months of age, 10 (36%) were 6 months–1 year, 7 (25%) were 1–2 years, and 1 (4%) was 2–5 years of age. The age distribution was similar to that of the original cohort. We found WUPyV-positive samples in most months, except for March 2008. Highest proportion of WUPyV-positive samples occurred in December 2008 (27%), followed by April 2008 (25%), November 2008 (22%), and February 2009 (19%).

We detected WUPyV VP2 fragment-positive specimens by multiplex PCR using the Seplex RV Detection kit-1 (Seegene, Seoul, South Korea) for other respiratory viruses, including adenovirus, parainfluenza viruses 1, 2, 3 (PIV1, 2, 3), influenza viruses A and B, rhinovirus (rhinovirus V), human metapneumovirus, respiratory syncytial virus A and B (RSV A, B), and coronaviruses OC43/HKU1 and 229E/NL63, according to the manufacturers' instructions. First strands

of cDNA were produced by using the RevertAid First Strand cDNA Synthesis Kit (Fermentas, Glen Burnie, MD, USA). Human bocavirus (HBoV) was tested as described previously (9).

Twenty (71%) case-patients were co-infected with other respiratory viruses, most commonly RSV B (9/28, 32%), followed by HBoV (6/28, 21%), rhinovirus V and PIV3 (4 each of 28, 14%), human metapneumovirus (3/28, 11%), adenovirus and influenza A (2 each of 28, 7%), and 229E (1/28, 4%). Of 20 patients with co-infections, 14 (50%) were infected with 2 viruses; 2 (7%) with 3 viruses (WU, RSV B, PIV3; and WU, influenza virus, A, HBoV); 3 (11%), with 4 viruses (WU, RSV B, PIV3, influenza A; WU, RSV B, PIV3, HBoV; and WU, RSV B, rhinovirus V, HBoV); and 1 (4%), with 5 viruses (WU, RSV B, PIV3, BoV, rhinovirus V).

Three (4%) of 68 throat swabs from outpatients with URTIs were WUPyV positive, substantially lower than from inpatients with LRTIs. Among 3 WUPyV-positive case-patients, 2 were 2 years of age and 1 was 3. No WUPyV was detected in 43 control samples.

The prevalence of WUPyV in hospitalized children with acute respiratory tract infections in Tianjin was 16.1%, higher than 7.1% found in a study in the United States (3); 4.9% in Germany (4); 4.5% in Australia (5); 6.29% in Thailand (6); and 2.2%

Table. Age distribution of children infected with WU polyomavirus, Tianjin, People's Republic of China, 2008–2009\*

Age	Inpatients with LRTIs	Outpatients with URTIs	Children without respiratory diseases
Mean ± SD, y	10.2 ± 16.1	5.96 ± 3.69	7.56 ± 4.25
Median age, y	0.4	5.0	7.0
Age group			
<6 mo	95 (54.6)	1 (1.5)	0
6 mo–<1 y	52 (29.9)	1 (1.5)	0
1–<2 y	15 (8.6)	3 (4.4)	2 (4.6)
2–5 y	9 (5.2)	25 (36.8)	11 (25.6)
>5 y	2 (1.1)	38 (55.9)	30 (69.8)
Unknown	1 (0.6)	0	0
Total	174 (100.0)	68 (100.0)	43 (100.0)

\* LRTIs, lower respiratory tract infections; URTIs, upper respiratory tract infections. Values are no. (%) unless otherwise indicated.